VERSETAMIDE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 508.0 | -3.3 | 5 | 10 | 198.0 | 22 | 0.75 |
- CAS
- 129009832
- UNII
- N78PI4C683
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 17 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00862459 | 2005-08-01 | Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | Phase 2 | Completed |
| NCT01092754 | 2002-05-01 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients | Phase 4 | Completed |